Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG

Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG Noor Ul Ain Rehman Sat, May 23, 2026 at 7:16 PM GMT+7 2 min read CERS Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, up 23% compared to the prior year period. Product revenue for fiscal Q1 2026 reached $53.7 million, reflecting a 24% growth over the prior year period.

Cerus Corporation (NASDAQ:CERS) raised its full-year product revenue guidance range to $227 million – $231 million, reflecting 10% to 12% year-over-year increase. Management attributed the strong start to 2026 to strength across the company’s business, in particular due to rising demand for its INTERCEPT Fibrinogen Complex. Cerus Corporation (NASDAQ:CERS) also announced a meaningful catalyst path in 2026, spanning anticipated regulatory, clinical, and pipeline milestones, which includes ongoing INTERCEPT RBC regulatory review in Europe, the Phase 3 RedeS readout in the U.S., and the planned U.S. PMA submission for its new INT200 illumination device.

Cerus Corporation (NASDAQ:CERS) is involved in the research, development, and manufacturing of biomedical and surgical products. The company produces blood systems for platelets and plasma, operates through the Blood Safety segment, and markets products under the INTERCEPT brand.